Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Samatasvir: Phase II started

Idenix began the double-blind Phase II HELIX-1 trial to evaluate 50, 100 and 150 mg oral samatasvir once daily for 12 weeks in combination with 150 mg oral

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE